MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases

PLoS One. 2021 Apr 14;16(4):e0250083. doi: 10.1371/journal.pone.0250083. eCollection 2021.

Abstract

Prior studies have demonstrated the utility of microRNA assays for predicting some cancer tissue origins, but these assays need to be further optimized for predicting the tissue origins of adenocarcinomas of the liver. We performed microRNA profiling on 195 frozen primary tumor samples using 14 types of tumors that were either adenocarcinomas or differentiated from adenocarcinomas. The 1-nearest neighbor method predicted tissue-of-origin in 33 samples of a test set, with an accuracy of 93.9% at feature selection p values ranging from 10-4 to 10-10. According to binary decision tree analyses, the overexpression of miR-30a and the underexpression of miR-200 family members (miR-200c and miR-141) differentiated intrahepatic cholangiocarcinomas from extrahepatic adenocarcinomas. When binary decision tree analyses were performed using the test set, the prediction accuracy was 84.8%. The overexpression of miR-30a and the reduced expressions of miR-200c, miR-141, and miR-425 could distinguish intrahepatic cholangiocarcinomas from liver metastases from the gastrointestinal tract.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adult
  • Aged
  • Bile Duct Neoplasms / genetics
  • Bile Ducts, Intrahepatic / metabolism
  • Biomarkers, Tumor / genetics
  • Cell Differentiation / genetics
  • Cholangiocarcinoma / genetics*
  • Cholangiocarcinoma / metabolism
  • Female
  • Gastrointestinal Neoplasms / genetics
  • Gastrointestinal Tract / metabolism
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Liver / cytology
  • Liver Neoplasms / genetics
  • Male
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Middle Aged
  • Neoplasm Metastasis / genetics

Substances

  • Biomarkers, Tumor
  • MIRN200 microRNA, human
  • MIRN30a microRNA, human
  • MicroRNAs

Grants and funding

This work was supported by Korea Health Industry Development Institute (HI19C0027), National Research Foundation of Korea(NRF) (2019R1A2C2010523) and National Cancer Center(NCC) (1910021/181095) Grants.